造口周围坏疽性脓皮病患者伤口管理的研究进展

doi:10.3761/j.issn.0254-1769.2024.22.019

摘要/Abstract

摘要：

造口周围坏疽性脓皮病是坏疽性脓皮病的一种亚型，其特征是在肠造口或尿路造口附近发生单发或多发性溃疡性病变，病情进展迅速，病因尚不明确。造口周围坏疽性脓皮病诊断困难、误诊率较高，患者疼痛剧烈，伤口易感染且愈合周期较长，严重影响患者的生活质量，也给护理工作带来极大挑战。该文综述了造口周围坏疽性脓皮病的诊断工具、影响伤口愈合的因素以及综合管理方法，旨在为制订造口周围坏疽性脓皮病伤口管理方案及提高其临床护理质量提供参考。

关键词: 坏疽性脓皮病, 肠造口术, 伤口感染, 综述, 护理

Abstract:

Peristomal pyoderma gangrenosum（PPG） is a subtype of pyoderma gangrenosum（PG） characterized by ulcerations surrounding an enterostomy or continent stoma. The disease progresses rapidly，and the cause is still unknown. As a result of the challenging diagnosis of PPG and the high rate of misdiagnosis，along with the severe pain experienced by patients，the vulnerability of wounds to infection，and the prolonged healing time，it has a substantial impact on the patient’s quality of life and presents significant challenges to medical professionals. This paper reviews the diagnostic tools for PPG，factors influencing wound healing，and integrated wound care methods. The aim is to provide a reference for developing wound care strategies for PPG and improving the quality of clinical nursing practices in China.

Key words: Pyoderma Gangrenosum, Enterostomy, Wound Infection, Review, Nursing Care

刘海佳, 刘丽萍, 余娇, 姚小燕. 造口周围坏疽性脓皮病患者伤口管理的研究进展[J]. 中华护理杂志, 2024, 59(22): 2805-2810.

LIU Haijia, LIU Liping, YU Jiao, YAO Xiaoyan. Research progress of wound care in patients with peristomal pyoderma gangrenosums[J]. Chinese Journal of Nursing, 2024, 59(22): 2805-2810.

参考文献 38

[1]	Maverakis E, Marzano AV, Le ST, et al. Pyoderma gangrenosum[J]. Nat Rev Dis Primers, 2020, 6(81):1-19.
[2]	Afifi L, Sanchez IM, Wallace MM, et al. Diagnosis and manage-ment of peristomal pyoderma gangrenosum:a systematic review[J]. J Am Acad Dermatol, 2018, 78(6):1195-1204.
[3]	Honma M, Sugawara M, Ueno N, et al. Clinical characteristics of peristomal pyoderma gangrenosum:a single center retrospective observational study[J]. J Dermatol, 2022, 49(11):1178-1182.
[4]	Jockenhöfer F, Wollina U, Salva KA, et al. The PARACELSUS score:a novel diagnostic tool for pyoderma gangrenosum[J]. Brit J Dermatol, 2019, 180(3):615-620.
[5]	胡清洁, 周敏, 姚煦. 坏疽性脓皮病36例临床特点分析及PARACELSUS评分与Delphi标准的比较[J]. 中华皮肤科杂志, 2023, 56(5):410-414.
	Hu QJ, Zhou M, Yao X. Analysis of clinical characteristics of 36 patients with pyoderma gangrenosum and comparison between the PARACELSUS score and Delphi criteria for their diagnosis[J]. Chin J Dermatol, 2023, 56(5):410-414.
[6]	Haag C, Hansen T, Hajar T, et al. Comparison of three diagnos-tic frameworks for pyoderma gangrenosum[J]. J Invest Dermatol, 2021, 141(1):59-63.
[7]	Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum:a Delphi consensus of inter-national experts[J]. JAMA Dermatol, 2018, 154(4):461-466. DOI PMID
[8]	Binus AM, Qureshi AA, Li VW, et al. Pyoderma gangrenosum:a retrospective review of patient characteristics,comorbidities and therapy in 103 patients[J]. Brit J Dermatol, 2011, 165(6):1244-1250.
[9]	Honigman A, Kelly RI. Pyoderma gangrenosum:a review of patient’s demographics,disease and treatment in 118 patients[J]. Australas J Dermatol, 2022, 63(2):267-269. DOI PMID
[10]	Su WPD, Davis MDP, Weenig RH, et al. Pyoderma gangreno-sum:clinicopathologic correlation and proposed diagnostic criteria[J]. Int J Dermatol, 2004, 43(11):790-800.
[11]	Kikuchi N, Yamamoto T. Peristomal pyoderma gangrenosum:report on 11 cases[J]. J Dermatol, 2020, 47(8):e282-e283.
[12]	Dissemond J, Marzano AV, Hampton PJ, et al. Pyoderma gan-grenosum:treatment options[J]. Drugs, 2023, 83(14):1255-1267. DOI PMID
[13]	Imaizumi K, Kasajima H, Terashima K, et al. Diagnosis and treatment difficulty in early-onset peristomal pyoderma gang-renosum associated with ulcerative colitis:a case report[J]. Cu-reus, 2022, 14(2):e22405.
[14]	Chong C, Palanisamy P, Yeo ES. Case to highlight a rare di-fferential diagnosis of necrotising fasciitis in the presence of a stoma:peristomal pyoderma gangrenosum[J]. BMJ Case Rep, 2021, 14(5):e237534.
[15]	Nowlin S, Manning L, Keefer L, et al. Perceptive eating as part of the journey in inflammatory bowel disease:lessons learned from lived experience[J]. Clin Nutr ESPEN, 2021, 41:299-304. DOI PMID
[16]	Migdanis A, Koukoulis G, Mamaloudis I, et al. The effect of a diverting ileostomy formation on nutritional status and energy intake of patients undergoing colorectal surgery[J]. Clin Nutr ESPEN, 2020, 40:357-362. DOI PMID
[17]	Cerdán Santacruz C, Lancharro Bermúdez M, Caparrós Sanz MR, et al. Peristomal pyoderma gangrenosum in a rectal cancer patient with an ileostomy:a case study[J]. J Wound Ostomy Continence Nurs, 2020, 47(4):403-406. DOI PMID
[18]	Crowson AN, Nuovo GJ, Mihm MC, et al. Cutaneous manifes-tations of Crohn’s disease,its spectrum,and its pathogenesis:intracellular consensus bacterial 16S rRNA is associated with the gastrointestinal but not the cutaneous manifestations of Crohn’s disease[J]. Hum Pathol, 2003, 34(11):1185-1192. PMID
[19]	Pearson WA, Prentice DA, Lim LY, et al. Clinical efficacy of crushed prednisolone and hydrocolloid powder in the primary treatment of peristomal pyoderma gangrenosum and correlation to in vitro drug release data[J]. Int Wound J, 2024, 21(3):e14808.
[20]	Burlando M, Paravisi A, Bodini G, et al. Crushed corticosteroid tablets in peristomal pyoderma gangrenosum:a case report[J]. J Wound Ostomy Continence Nurs, 2021, 48(5):460-462. DOI PMID
[21]	Barbosa NS, Tolkachjov SN, El-Azhary RA, et al. Clinical fea-tures,causes,treatments,and outcomes of peristomal pyoderma gangrenosum(PPG) in 44 patients:the Mayo Clinic experien-ce,1996 through 2013[J]. J Am Acad Dermatol, 2016, 75(5):931-939. DOI PMID
[22]	Wang J, Prenner J, Wang W, et al. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2020, 51(12):1365-1372.
[23]	Yamamoto T, Yamasaki K, Yamanaka K, et al. Clinical guidance of pyoderma gangrenosum 2022[J]. J Dermatol, 2023, 50(9):e253-e275.
[24]	Chen B, Li W, Qu B. Practical aspects of the diagnosis and management of pyoderma gangrenosum[J]. Front Med(Lausan-ne), 2023, 10:1134939.
[25]	陈梦越, 李乐之. 慢性伤口细菌生物膜相关微环境的研究进展[J]. 中华护理杂志, 2016, 51(12):1483-1486.
	Chen MY, Li LZ. Research of progress on microenvironment of bacterial biofilms on chronic wounds[J]. Chin J Nurs, 2016, 51(12):1483-1486.
[26]	Lyons D, Eustace K, Denham M, et al. Treatment-resistant pyo-derma gangrenosum managed with maggot debridement therapy and hyperbaric oxygen therapy:a case study[J]. Wounds UK, 2023, 19(4):53-55.
[27]	Toyoda T, Mitsuyama S, Nagao E, et al. Topical management of peristomal pyoderma gangrenosum:a report of 3 case studies[J]. J Wound Ostomy Continence Nurs, 2021, 48(4):345-349.
[28]	Prakash D, Prasad PVS, Kaviarasan PK, et al. Case series of pyoderma gangrenosum successfully managed with biological dressing[J]. J Med Sci Clinl Res, 2017, 5(11):30976-30982.
[29]	Li WZ, Wang XQ, Liu LR, et al. Supramolecular coordination platinum metallacycle-based multilevel wound dressing for bacteria sensing and wound healing[J]. Proc Natl Acad Sci USA, 2024, 121(14):e2318391121.
[30]	孟晓红, 袁秀群. 凸面造口产品使用的国际专家共识解读和临床应用启示[J]. 护理研究, 2018, 32(13):1993-1996.
	Meng XH, Yuan XQ. International experts’ consensus interpre-tation and clinical implications on use of convex stoma products[J]. Chin Nurs Res, 2018, 32(13):1993-1996.
[31]	孙懿松, 许方蕾, 黄盛松. 结肠造口并发坏疽性脓皮病1例多学科团队合作护理[J]. 上海护理, 2019, 19(6):61-63.
	Sun YS, Xu FL, Huang SS. Multidisciplinary team cooperation nursing for 1 case of colostomy complicated with pyoderma gangrenosum[J]. Shanghai Nurs, 2019, 19(6):61-63.
[32]	Farley P. Should topical opioid analgesics be regarded as effec-tive and safe when applied to chronic cutaneous lesions?[J]. J Pharm Pharmacol, 2011, 63(6):747-756. DOI PMID
[33]	Maida V, Corban J. Topical medical cannabis:a new treatment for wound pain-three cases of pyoderma gangrenosum[J]. J Pain Symptom Manag, 2017, 54(5):732-736.
[34]	张媛, 郭锦丽. 沉浸式虚拟现实技术在创面操作性疼痛管理中的应用进展[J]. 中华护理杂志, 2023, 58(2):243-249. DOI URL
	Zhang Y, Guo JL. Application progress of immersive virtual reality technology in wound procedural pain management[J]. Chin J Nurs, 2023, 58(2):243-249. DOI URL
[35]	Zeina T, Levy AN. Adjunctive hyperbaric oxygen therapy for high risk peristomal pyoderma gangrenosum[J]. Dig Dis Sci, 2022, 67(10):4597-4598.
[36]	Seo HI, Lee HJ, Han KH. Hyperbaric oxygen therapy for pyo-derma gangrenosum associated with ulcerative colitis[J]. Intest Res, 2018, 16(1):155-157.
[37]	朱小妹, 谌永毅, 韦迪, 等. 新型冠状病毒肺炎疫情下基于互联网平台的慢性伤口居家照护体系构建与实践[J]. 中华护理杂志, 2020, 55(增刊):799-802.
	Zhu XM, Chen YY, Wei D, et al. Construction and practice of home care system for chronic wound based on internet platform under the prevalence of coronavirus disease 2019[J]. Chin J Nurs, 2020, 55(Suppl):799-802.
[38]	Reznikov EA, Suskind DL. Current nutritional therapies in in-flammatory bowel disease:improving clinical remission rates and sustainability of long-term dietary therapies[J]. Nutrients, 2023, 15(3):668.